SPEAKERS
Read More
Dr. Marshall received his training at Duke University, the University of Louisville, and Georgetown University. Dr. Marshall is an internationally recognized expert in new drug development for GI cancer, with expertise in phase I, II, and III trial design, and has served as Principal Investigator for more than one hundred clinical trials throughout his career.
Read More
Dr. Doug Johnson recently joined the Vanderbilt faculty in the Division of Hematology/Oncology with a focus on melanoma and a broader interest in molecular profiling, targeted therapy, and immune therapy across cancer types. After growing up in San Antonio, TX, he completed medical school at the University of Alabama at Birmingham, residency at Duke University, and, more recently, a fellowship and the MSCI program at Vanderbilt. He is now on the physician-scientist track performing clinical and translational research. Dr. Johnson's primary scientific interests are in developing and understanding biomarkers for immune and targeted therapeutics and developing clinical trials for melanoma patients.
Read More
Dr. Liron Pantanowitz is the Maud Menten Professor and Chair of the Department of Pathology at UPMC and the University of Pittsburgh. He received his BScHons, Medical Degree, and PhD from the University of Witwatersrand in South Africa. He subsequently completed his anatomical and clinical pathology residency training at Beth Israel Deaconess Medical Center, Harvard in Boston. He then completed a hematopathology fellowship at Harvard and Cytopathology fellowship at Baystate Medical Center, Tufts University.
Read More
William K. Oh, MD, is Clinical Professor of Medicine at the Icahn School of Medicine at Mount Sinai. He is an expert in the management of genitourinary malignancies, including prostate, renal, bladder, and testicular cancers. Dr. Oh is also Chief Medical Officer at the Prostate Cancer Foundation, the world’s leading prostate cancer philanthropy. Dr. Oh served as Chief of the Division of Hematology and Medical Oncology at Mount Sinai from 2009 to 2020 and as Deputy Director of The Tisch Cancer Institute at Mount Sinai from 2017 to 2020. He was also CMO at Sema4, a genomics and health intelligence company.
Read More
Michael R. Bishop, MD, specializes in the diagnosis and treatment of lymphomas. In particular, he cares for patients with hematologic malignancies that have not responded to first-line treatments. An expert in hematopoietic stem cell transplantation (bone marrow transplantation) and cellular therapy, Dr. Bishop and his team are working to address the unique social, economic, physiological and biological issues that patients face while undergoing this treatment.
Read More
Dr. Nancy Davidson is the executive vice president of Clinical Affairs at Fred Hutch. She serves as a bridge builder across the cancer treatment and research programs of the Fred Hutch/University of Washington/Seattle Children's Cancer Consortium. Dr. Davidson, a breast cancer oncologist, has built a worldwide reputation for her expertise and leadership in this field, for her research teasing out the role of hormones in breast cancer growth, and for her impact on the development of new standards of care. Her team was the first to describe how the activity of one of the estrogen receptor genes is regulated by epigenetic factors, which affect how the DNA code is read and translated into proteins.
Read More
Christian Rolfo, MD, PhD, has been appointed the director of the Division of Medical Oncology at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James). He will start on Aug. 15.
Rolfo will serve as a professor in The Ohio State University College of Medicine, Department of Internal Medicine, and as associate director for early phase clinical trials in Ohio State’s Comprehensive Cancer Center. He will oversee more than 65 faculty who provide subspecialized care and/or conduct research for breast, endocrine, gastrointestinal, genitourinary, lung, skin and head and neck cancers as well as sarcoma.
MODERATORS
Muhammad Riaz, MD
St. Elizabeth
Jayadev Mettu, MD
Oncology Hematology Care
Robert L. Cody, MD
Robert L. Cody, MD
Lauren Mendelson, DO
University of Cincinnati
Daniel Flora, MD
St. Elizabeth
Alexander Starodub, MD
The Christ Hospital
Tahir Latif, MBBS, MBA
University of Cincinnati
Seerin Viviane Shatavi, MD
TriHealth
Jennifer L. Leddon, MD, PhD
University of Cincinnati
Philip D. Leming, MD
Cincinnati Cancer Advisors
Olugbenga Olowokure, MD
University of Cincinnati
Minsig Choi, MD
St. Elizabeth
James H. Essell, MD
Oncology Hematology Care
Mufti Naeem Ahmad, MD
TriHealth